AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1478163
Drug: Macrocrystalline nitrofurantoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macrocrystalline nitrofurantoin 50 mg
Trial: 22877506
Drug: Prophylactic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic platelet transfusion strategy (transfusion when platelet counts were 10×10(9) per L or lower)
Trial: 3307717
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% ALO 2145 (p‐aminoclonidine hydrochloride)
Trial: 31201057
Drug: Automated reminder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated reminder to recommend the 2nd or 3rd dose of HPV vaccine
Trial: 26054139
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (basic treatment combined with oral administration of regular antidiabetics)
Trial: 19916293
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between acupuncture and medication groups
Trial: 9246043
Drug: IFN 3
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN 3 MU three times a week + UDCA 250 mg twice a day
Trial: 9246043
Drug: UDCA alone
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA alone 250 mg twice a day
Trial: 3326393
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg oral PGE2 given hourly for two 12-h periods
Trial: 3326393
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PGE2 priming and induction of labor with oxytocin
Trial: 22317756
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (25 μg/d as cholecalciferol)
Trial: 20075050
Drug: Pre- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- and post-bronchodilator spirometry or a single bronchial challenge test
Trial: 20075050
Drug: Tapering of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering of asthma medications and repeated bronchial challenge tests
Trial: 9613362
Drug: Gulliver (G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gulliver (G)
Trial: 9613362
Drug: Gulliver (G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gulliver (G) and Book/Tape Method (TM)
Trial: 7992933
Drug: Amoxicillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (1 g intravenous injection immediately after induction of anaesthesia, followed by postoperative injections every 6 hours for 36 hours, total of 6 injections)
Trial: 7992933
Drug: Cefamandole (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (1.5 g intravenous injection immediately after induction of anaesthesia, followed by postoperative injections every 6 hours for 36 hours, total of 6 injections)
Trial: 26707087
Drug: .20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: .20 mg/kg esketamine
Trial: 26707087
Drug: .40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: .40 mg/kg esketamine
Trial: 24883300
Drug: 0.30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 mg/kg rectal midazolam diluted with 5 mL saline (Group M)
Trial: 24883300
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL saline (Group C)
Trial: 22467361
Drug: Resource-oriented cognitive-behavioral
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resource-oriented cognitive-behavioral therapy (ROCBT)
Trial: 20554904
Drug: Oral sea
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sea buckthorn (SB) oil, 2 g daily for 3 months
Trial: 20554904
Drug: Placebo oil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oil, 2 g daily for 3 months
Trial: 20554904
Drug: Oral sea
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sea buckthorn (SB) oil
Trial: 15750155
Drug: Biphasic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biphasic injection (90 and 50 mL at 3 and 1.5 mL/s) of intravenous contrast (300 mg/mL iodine)
Trial: 15750155
Drug: Triple-phase injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-phase injection (90, 40, and 40 mL at 3, 2, and 1.5 mL/s)
Trial: 15750155
Drug: Dual-phase injection
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-phase injection (80 and 60 mL at 3 and 1.5 mL/s) in the caudocranial direction with a 50-s delay
Trial: 15750155
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous contrast agent
Trial: 10989865
Drug: Ketamine 5
RxNorm normalized name: ketamine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 5 mg iv
Trial: 10989865
Drug: Saline 2
RxNorm normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 2 ml iv
Trial: 1424430
Drug: l-methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-methylphenidate
Trial: 22726401
Drug: Beta-blocker titration
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-blocker titration
Trial: 11696811
Drug: Alarm therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alarm therapy combined with 40 microg intranasal desmopressin for 3 weeks followed by 20 microg desmopressin for 3 weeks (group 1)
Trial: 11696811
Drug: Alarm therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alarm therapy and placebo (group 2)
Trial: 11696811
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment modalities (group 1 and group 2)
Trial: 9216706
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy plus radiotherapy (Arm B)
Trial: 9216706
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy alone (Arm A)
Trial: 2213264
Drug: Tocolysis and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocolysis and prophylactic antibiotic administration
Trial: 2213264
Drug: Other antibiotics
RxNorm normalized name: Other antibiotics for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antibiotics (cefoxitin, cefazolin, ampicillin)
Trial: 30149148
Drug: G‐CSF +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF + plerixafor
Trial: 9216955
Drug: Melatonin (Mel)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin (Mel) 5 mg po administered at 1300
Trial: 7970472
Drug: Intrapartum intrathecal
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrapartum intrathecal narcotic analgesia (25 micrograms fentanyl and 0.25 mg morphine sulfate)
Trial: 3313684
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy for 6 months
Trial: 19832996
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care (case manager coordinated support and brief psychological treatment, enhanced specialist and GP communication)
Trial: 11318768
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg daily if creatinine < 150 micromol l‐1 or 100 mg if creatinine > 150 micromol l‐1)
Trial: 10481379
Drug: Euthyroidism after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euthyroidism after surgical treatment
Trial: 6373102
Drug: Prochlorperazine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine (6 mg/sq m)
Trial: 6373102
Drug: Haloperidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (1 mg/sq m)
Trial: 6373102
Drug: Droperidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (1 mg/sq m)
Trial: 31834923
Drug: Telephone administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone administration of the Patient-Specific Functional Scale (PSFS)
Trial: 31834923
Drug: In-person administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person administration of the Patient-Specific Functional Scale (PSFS)
Trial: 29743962
Drug: Fentanyl (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (50 mg)
Trial: 19750873
Drug: Prismatic displacement
RxNorm normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Volition Prismatic Luminizing Shield]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prismatic displacement adaptation with a concurrent cognitive task (serial subtractions of 7)
Trial: 19750873
Drug: Prismatic displacement
RxNorm normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Volition Prismatic Luminizing Shield]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prismatic displacement adaptation with a concurrent cognitive task (repeating back tones)
Trial: 19750873
Drug: Prismatic displacement
RxNorm normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Volition Prismatic Luminizing Shield]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prismatic displacement adaptation without a concurrent cognitive task
Trial: 17578562
Drug: 17OHPC (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17OHPC (250 mg intramuscular injections weekly from 16-20 weeks up to 36 weeks)
Trial: 1850282
Drug: Balanced Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced Saline Solution Plus (BSS Plus)
Trial: 29024419
Drug: EpiFix and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EpiFix and multilayer compression therapy
Trial: 29024419
Drug: Standard wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard wound care and multilayer compression therapy
Trial: 27588078
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment + oral administration of Jiawei Di Tan Tang
Trial: 22568808
Drug: Roledumab (30-3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roledumab (30-3000 μg i.v. and 300 μg i.m.)
Trial: 22568808
Drug: Roledumab (30-3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roledumab (30-3000 μg i.v.)
Trial: 22568808
Drug: Roledumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roledumab (300 μg i.m.)
Trial: 11932063
Drug: PCA morphine
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA morphine 1 mg/cc plus naloxone 6 microg/cc
Trial: 11932063
Drug: PCA morphine
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA morphine 1 mg/cc plus normal saline
Trial: 8154643
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g every 8 h)
Trial: 8154643
Drug: Piperacillin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (12 to 18 g/d in 4 to 6 divided doses) plus Tobramycin (1.7 to 2.0 mg/kg body weight every 8 h)
Trial: 2830091
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg twice a day
Trial: 31832821
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate (1.4 mg/m2 on days 1 and 8 every 21 days)
Trial: 31832821
Drug: Vinorelbine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (25 mg/m2 on days 1, 8, and 15 every 21 days)
Trial: 16774980
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR 2.0-3.0)
Trial: 29122636
Drug: Apixaban vs
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban vs Warfarin
Trial: 20934155
Drug: Intermittent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent administration of tisokinase (960,000 IU)
Trial: 20934155
Drug: Continuous irrigation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous irrigation using pH-adjusted lactate Ringer's solution containing tisokinase (96 IU/mL) infused at 20 mL/hr for 48 hours
Trial: 20934155
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated only with baseline treatment
Trial: 12576372
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who maintained their warfarin dose
Trial: 12576372
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who decreased their dose by 1 to 20%
Trial: 12576372
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who decreased their dose by 21 to 43%
Trial: 8542169
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms budesonide (single evening dose)
Trial: 8542169
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms budesonide (twice daily for 2 weeks)
Trial: 6233335
Drug: Isotretinoin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 0.1 mg/kg/day
Trial: 27164459
Drug: 94 mL
RxNorm normalized name: ethanol 0.94 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 94 mL of prewarmed iopromide 240 mg I/mL at 8.3 mL/s
Trial: 27164459
Drug: 75 mL
RxNorm normalized name: ethanol 0.75 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mL of 300 mg I/mL at 6.7 mL/s
Trial: 27164459
Drug: 61 mL
RxNorm normalized name: ethanol 0.61 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 61 mL of 370 mg I/mL at 5.4 mL/s
Trial: 22523335
Drug: Bradykinin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bradykinin infusion in the left leg (Study I)
Trial: 17660604
Drug: Depakin-chrono, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depakin-chrono, 500 mg tablets, daily dose varied 250-1500 mg/day
Trial: 2182578
Drug: Chemotherapy (included
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (included in some trials)
Trial: 7000250
Drug: Clindamycin injection
RxNorm normalized name: clindamycin Injection
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin injection before operation and antibiotic capsules after operation
Trial: 7000250
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection and antibiotic capsules
Trial: 7000250
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection and placebo capsules
Trial: 7000250
Drug: Clindamycin injection
RxNorm normalized name: clindamycin Injection
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin injection before operation
Trial: 7000250
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic injection
Trial: 27997703
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine administered on day 1 of chemotherapy (n=43)
Trial: 27997703
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine administered on day 11 of chemotherapy (n=54)
Trial: 21729116
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride drops orally at a dose of 0.7 mg/kg
Trial: 11374408
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1.5 g b.i.d.
Trial: 11374408
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 1-2 mg/kg
Trial: 9243683
Drug: Intranasal ketamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine, 3 mg.kg‐1, diluted to 2 ml with saline, 1 ml per naris
Trial: 9243683
Drug: Placebo (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intranasal saline, 2 ml, 1 ml per naris)
Trial: 2830047
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (1 mg)
Trial: 2821784
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (2 mg)
Trial: 2843305
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (10 mg)
Trial: 24925006
Drug: Vancomycin for
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin for inhalation (250 mg twice a day)
Trial: 23388602
Drug: Cavinton in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavinton in infusions and then in tablets (cavinton forte)
Trial: 23388602
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without cavinton
Trial: 17450677
Drug: IL-1 beta
RxNorm normalized name: Heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IGg1 and part of human IL1 receptor accessory protein
DrugBank: Goflikicept (DB16396)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-1 beta antagonist (single intraarticular injection of 50 or 150 mg)
Trial: 17450677
Drug: IL-1 beta
RxNorm normalized name: Heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IGg1 and part of human IL1 receptor accessory protein
DrugBank: Goflikicept (DB16396)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-1 beta antagonist (150 mg)
Trial: 17450677
Drug: Anti-TNF alpha
RxNorm normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF alpha therapy
Trial: 12755009
Drug: Angiotensin-II receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-II receptor blockers
Trial: 6331100
Drug: standard aftercare
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard aftercare treatment arrangements (Control group, N = 25)
Trial: 30157824
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care for neurogenic bladder (NGB) including anticholinergic medications and usual bladder management strategies
Trial: 26756747
Drug: Dorzolamide/Timolol Fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide/Timolol Fixed Combination (DTFC)
Trial: 25175099
Drug: Erlotinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib plus bevacizumab (150 mg/day erlotinib + 15 mg/kg bevacizumab every 3 weeks)
Trial: 25175099
Drug: Erlotinib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib alone (150 mg/day)
Trial: 21335480
Drug: Pharmacist care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist care program (regular drug-counseling sessions with pharmacists)
Trial: 9564798
Drug: High starting
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High starting dose of 1 mg budesonide twice daily followed by a stepwise decrease of 25% every second day for 1 week (group A)
Trial: 9564798
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of 0.25 mg budesonide twice daily for 1 week (group B)
Trial: 2741904
Drug: Mailed self‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mailed self‐administered questionnaire
Trial: 31960447
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment containing 5% pyridine-2, 4-dicarboxylic acid diethyl ester and 0.25% resveratrol
Trial: 10451911
Drug: Mirtazapine 15
RxNorm normalized name: mirtazapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 15 mg
Trial: 23052571
Drug: Trazodone 25
RxNorm normalized name: trazodone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 25 mg
Trial: 16690128
Drug: 0.59-mg fluocinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.59-mg fluocinolone acetonide implant
Trial: 16690128
Drug: 2.1-mg fluocinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.1-mg fluocinolone acetonide implant
Trial: 16690128
Drug: 0.59-mg and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.59-mg and 2.1-mg fluocinolone acetonide implants
Trial: 16287954
Drug: High-dose atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose atorvastatin (80 mg/d; n = 4439)